What is the share price of Solara Active Pharma Sciences Ltd (SOLARA) today?
The share price of SOLARA as on 28th March 2025 is ₹513.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Solara Active Pharma Sciences Ltd (SOLARA) share?
The past returns of Solara Active Pharma Sciences Ltd (SOLARA) share are- Past 1 week: -0.69%
- Past 1 month: 10.09%
- Past 3 months: -24.00%
- Past 6 months: -34.86%
- Past 1 year: 50.13%
- Past 3 years: -18.69%
- Past 5 years: 30.73%
What are the peers or stocks similar to Solara Active Pharma Sciences Ltd (SOLARA)?
The peers or stocks similar to Solara Active Pharma Sciences Ltd (SOLARA) include:What is the market cap of Solara Active Pharma Sciences Ltd (SOLARA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Solara Active Pharma Sciences Ltd (SOLARA) is ₹2779.96 Cr as of 28th March 2025.What is the 52 week high and low of Solara Active Pharma Sciences Ltd (SOLARA) share?
The 52-week high of Solara Active Pharma Sciences Ltd (SOLARA) is ₹882.80 and the 52-week low is ₹340.96.What is the PE and PB ratio of Solara Active Pharma Sciences Ltd (SOLARA) stock?
The P/E (price-to-earnings) ratio of Solara Active Pharma Sciences Ltd (SOLARA) is -4.90. The P/B (price-to-book) ratio is 2.97.Which sector does Solara Active Pharma Sciences Ltd (SOLARA) belong to?
Solara Active Pharma Sciences Ltd (SOLARA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Solara Active Pharma Sciences Ltd (SOLARA) shares?
You can directly buy Solara Active Pharma Sciences Ltd (SOLARA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Solara Active Pharma Sciences Ltd
SOLARA Share Price
513.200.50% (+2.55)
SOLARA Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
SOLARA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -11.00 | 2.97 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.27 | 6.30 | 0.54% |
SOLARA Analyst Ratings & Forecast
Detailed Forecast 0%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
SOLARA Company Profile
SSL Pharma Sciences is a manufacturer of pharmaceutical preparation
SOLARA Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
44.07
1Y Return
7.04%
Buy Reco %
88.24
CIPLA
PE Ratio
28.93
1Y Return
3.66%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
65.78
1Y Return
24.12%
Buy Reco %
68.00
MANKIND
PE Ratio
51.84
1Y Return
5.39%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.40
1Y Return
7.09%
Buy Reco %
45.16
SOLARA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SOLARA Stock Summary · January 2025
The company is currently grappling with revenue challenges due to heightened pricing competition, prompting a cautious revision of its FY '25 revenue guidance to Rs. 1,300 to Rs. 1,400 crores. Despite these setbacks, management remains optimistic about margin improvements, with gross margins rising to 55% and expectations of stabilizing EBITDA margins around 20%. Strategic focus on the underperforming CRAMS segment is anticipated to drive future growth, supported by investments in the FDA-approved Vizag facility and plans to enhance operational capabilities through talent acquisition. While debt management remains a priority, with a target to reduce the debt to EBITDA ratio to under 1.5 times, the company is committed to maintaining financial health and exploring international market opportunities.
Key Points on SOLARA Stock Performance
SOLARA Stock Growth Drivers
6Margin Expansion and Financial Health
The company has achieved a gross margin expansion of 500 basis points, contributing to improved
Strategic Focus on CRAMS Business
The company is strategically focusing on its CRAMS (Contract Research and Manufacturing Services) business, which
SOLARA Stock Challenges
5Disappointing Revenue Performance
The company reported a disappointing quarter with a decline in revenue attributed to increased pricing
Debt Management Challenges
While the company has made progress in reducing its debt from nearly 6 times debt
SOLARA Forecasts
Price
Revenue
Earnings
SOLARA Share Price Forecast
2024
Current
₹513.20
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹513.20
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SOLARA Company Revenue Forecast
2024
Current
₹1.29
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2024
Current
₹1.29
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SOLARA Stock EPS (Earnings Per Share) Forecast
2024
Current
₹-145.27
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹-145.27
Baseline
Forecast for Mar 2025
High
₹—
Median
₹—
Low
₹—
All values in ₹
SOLARA
Income
Balance Sheet
Cash Flow
Annual Normal View
SOLARA Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 523.43 | 1,399.06 | 1,349.27 | 1,645.65 | 1,288.36 | 1,466.36 | 1,294.29 | 1,314.25 | ||||||||
Raw Materials | 274.29 | 738.62 | 653.03 | 726.57 | 912.64 | 781.78 | 765.75 | 1,261.69 | ||||||||
| Power & Fuel Cost | 31.41 | 79.35 | 77.68 | 85.42 | 93.70 | 108.10 | 122.56 | |||||||||
| Employee Cost | 68.53 | 185.81 | 204.13 | 229.37 | 236.34 | 228.63 | 243.92 | |||||||||
| Selling & Administrative Expenses | 22.66 | 64.48 | 69.23 | 73.77 | 74.60 | 66.93 | 70.53 | |||||||||
| Operating & Other expenses | 67.23 | 105.29 | 58.24 | 115.88 | -125.42 | 124.49 | 371.51 | |||||||||
EBITDA | 59.31 | 225.51 | 286.96 | 414.64 | 96.50 | 156.43 | -279.98 | 52.56 | ||||||||
| Depreciation/Amortization | 33.98 | 83.10 | 94.16 | 108.66 | 112.32 | 111.19 | 103.33 | 100.20 | ||||||||
| PBIT | 25.33 | 142.41 | 192.80 | 305.98 | -15.82 | 45.24 | -383.31 | -47.64 | ||||||||
| Interest & Other Items | 25.14 | 82.42 | 77.89 | 84.48 | 75.28 | 90.06 | 105.11 | 116.38 | ||||||||
| PBT | 0.19 | 59.99 | 114.91 | 221.50 | -91.10 | -44.82 | -488.42 | -164.02 | ||||||||
| Taxes & Other Items | -0.18 | 0.48 | 0.30 | 0.10 | -32.95 | -22.64 | 78.97 | 88.68 | ||||||||
| Net Income | 0.37 | 59.51 | 114.61 | 221.40 | -58.15 | -22.18 | -567.39 | -252.70 | ||||||||
| EPS | 0.14 | 21.74 | 40.14 | 65.00 | -14.90 | -5.68 | -145.27 | -64.70 | ||||||||
| DPS | 0.00 | 4.61 | 1.84 | 6.45 | 0.00 | 2.76 | 0.00 | 0.00 | ||||||||
| Payout ratio | 0.00 | 0.21 | 0.05 | 0.10 | 0.00 | — | 0.00 | 0.00 |
SOLARA Company Updates
SOLARA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Solara Active Pharma Sciences Ltd | -4.90 | 2.97 | — |
| Sun Pharmaceutical Industries Ltd | 44.07 | 6.29 | 0.77% |
| Cipla Ltd | 28.93 | 4.45 | 0.88% |
| Torrent Pharmaceuticals Ltd | 65.78 | 15.89 | 0.87% |
SOLARA Stock Price Comparison
Compare SOLARA with any stock or ETFCompare SOLARA with any stock or ETF
SOLARA
SOLARA Shareholdings
SOLARA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
SOLARA Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 2.87%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SOLARA Shareholding Pattern
SOLARA Shareholding History
Foreign Institutions
Mutual Funds Invested in SOLARA
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 4 Mutual Funds holding Solara Active Pharma Sciences Ltd
| Funds (Top 4) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7140% | Percentage of the fund’s portfolio invested in the stock 0.10% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 90/91 (-9) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2210% | Percentage of the fund’s portfolio invested in the stock 0.12% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/100 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.1105% | Percentage of the fund’s portfolio invested in the stock 0.31% | Change in the portfolio weight of the stock over the last 3 months -0.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 34/74 (-1) |
Compare 3-month MF holding change on Screener
smallcases containing SOLARA stock
Looks like this stock is not in any smallcase yet.
SOLARA Events
SOLARA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SOLARA Upcoming Dividends
No upcoming dividends are available
SOLARA Past Dividends
Cash Dividend
Ex DateEx DateAug 18, 2021
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Aug 18, 2021
Cash Dividend
Ex DateEx DateNov 19, 2020
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 19, 2020
Cash Dividend
Ex DateEx DateJul 28, 2020
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 28, 2020
Cash Dividend
Ex DateEx DateAug 6, 2019
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 6, 2019
SOLARA Stock News & Opinions
Articles & Videos
Corporate
Solara Active Pharma Sciences to convene board meeting
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 2 April 2025.Powered by Capital Market - Live
1 day agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to hold board meeting
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 26 March 2025.Powered by Capital Market - Live
6 days agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to incorporate wholly owned subsidiary
Solara Active Pharma Sciences approved the incorporation of wholly owned subsidiary in relation to proposed demerger of the CRAMS and Polymers Business into an independent listed entity. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Solara Active Pharma Sciences reports consolidated net profit of Rs 8.09 crore in the December 2024 quarter
Net profit of Solara Active Pharma Sciences reported to Rs 8.09 crore in the quarter ended December 2024 as against net loss of Rs 275.34 crore during the previous quarter ended December 2023. Sales rose 41.70% to Rs 300.31 crore in the quarter ended December 2024 as against Rs 211.94 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales300.31211.94 42 OPM %19.21-76.29 - PBDT32.63-186.61 LP PBT8.09-212.57 LP NP8.09-275.34 LP Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences announces board meeting date
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Solara Active Pharma Sciences Ltd Surges 2.77%
Solara Active Pharma Sciences Ltd gained 2.77% today to trade at Rs 688. The BSE Healthcare index is up 0.18% to quote at 45033.49. The index is up 1.18 % over last one month. Among the other constituents of the index, Ami Organics Ltd increased 2.56% and Innova Captab Ltd added 2.53% on the day. The BSE Healthcare index went up 39.68 % over last one year compared to the 9.34% surge in benchmark SENSEX. Solara Active Pharma Sciences Ltd has lost 12.6% over last one month compared to 1.18% gain in BSE Healthcare index and 4.52% drop in the SENSEX. On the BSE, 30 shares were traded in the counter so far compared with average daily volumes of 13010 shares in the past one month. The stock hit a record high of Rs 885.95 on 02 Dec 2024. The stock hit a 52-week low of Rs 321.93 on 15 Feb 2024.Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Solara Active Pharma Sciences reports consolidated net profit of Rs 8.01 crore in the September 2024 quarter
Net profit of Solara Active Pharma Sciences reported to Rs 8.01 crore in the quarter ended September 2024 as against net loss of Rs 17.16 crore during the previous quarter ended September 2023. Sales declined 18.41% to Rs 346.95 crore in the quarter ended September 2024 as against Rs 425.24 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales346.95425.24 -18 OPM %17.678.85 - PBDT33.3514.37 132 PBT8.01-11.84 LP NP8.01-17.16 LP Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences allots 49,000 equity shares under ESOP
Solara Active Pharma Sciences has allotted 49,000 equity shares under ESOP on 21 October 2024. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to declare Quarterly Result
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 21 October 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences schedules AGM
Solara Active Pharma Sciences announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -1.54%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 0.64% to 0.34%